SenoSENSE Medical Systems Announces Enrollment Completed in Study of Novel Device to Measure Breast Density

TORONTO--(Marketwire - October 25, 2012) - SenoSENSE Medical Systems Inc., a medical device company engaged in the development of innovative technologies targeted to reducing the impact of breast cancer, announced today that it has completed enrollment of a 100 patient study evaluating the effectiveness of the company’s Electrical Breast Densitometer™ system. The Electrical Breast Densitometer evaluates breast density using a proprietary Densitrode™ sensor and electronics. The density test is painless, emits no radiation, and takes less than a minute. The initial study was undertaken at Timmins and District Hospital under the direction of Principal Investigator Dr. Karina Bukhanov, Breast Radiologist affiliated with Mount Sinai Hospital Marvelle Koffler Breast Centre and Gattuso Rapid Diagnosis Clinic at Princess Margaret Hospital. The results of the first 20 patients enrolled in the study were recently presented at the ASCO Breast Cancer Symposium and show that the technique is accurate and highly reproducible.

“Breast density is one of the major factors in developing breast cancer,” noted Dr. Bukhanov. “A woman who has extremely dense breasts is at approximately five times the risk of developing the disease compared to a woman who has breasts with fatty, low-density tissue. Our ability to identify these women will allow us to screen this population more effectively and also permit these women to implement risk prevention techniques.”

“The completion of the initial human study evaluating Densitrode™ breast density technology represents an important milestone in advancing an exciting new technology,” commented Joel Ironstone, President and Chief Executive Officer of SenoSENSE Medical Systems. “We believe that the Electrical Breast Densitometer offers great promise to identify younger women who are at increased risk of breast cancer and enable proactive intervention to reduce their risk and initiate earlier surveillance in order to identify cancer at an earlier and more treatable stage.”

About SenoSENSE Medical Systems Inc.
SenoSENSE Medical Systems is a Toronto, Ontario-based early-stage medical device company developing technology that enables personalized management of breast cancer risk. The company’s first product, the Electrical Breast Densitometer, employs proprietary Densitrode™ technology to assess and monitor breast density, the most significant non-genetic risk factor for breast cancer. Breast cancer remains an unsolved problem and represents the most prevalent cause of death in women under the age of 50.